紫杉醇联合化疗方案治疗晚期乳腺癌的临床研究

目的评价含紫杉醇（Taxol）化疗方案治疗晚期乳腺癌的临床疗效和毒性反应。方法选择应用紫杉醇联合化疗方案治疗晚期乳腺癌患者76例，其中Taxol＋表阿霉素（EPI）25例，Taxol＋吡喃阿霉素（THP）22例，Taxol＋EPI＋环磷酰胺（CTX）8例，Taxol＋THP＋CTX12例，Taxol＋希罗达9例。结果76例患者均可评价疗效，完全缓解（CR）4例，占5．26％；部分缓解（PR）49例，占64．47％，总有效率69．74％。稳定（SD）14例，占18．42％；进展（PD）9例，占11．84％。中位TTP为8．3个月，中位生存期为9.8个月。主要毒副反应为白细胞减少69例（90．79％），脱发70例（92．11％），肌肉关节酸痛61例（80．26％）等，无严重超敏反应。结论对于晚期乳腺癌患者使用以紫杉醇为主的联合化疗方案具有较好的临床疗效，同时其不良反应可以耐受，是治疗晚期乳腺癌较好的一线化疗方案。

Study of Taxol-based chemotherapy in the treatment of advanced breast cancer

Objective To evaluate the efficacy and toxicity of taxol-based chemotherapy in the treatment of advanced breast cancer.Methods Seventy-six patients with breast cancer treated with taxol-based protocols: taxol plus epirubicin 25 patients, taxol plus pirarubicin 22 patients, taxol plus epirubicin plus cytoxan 8 patients, taxol plus pirarubicin plus cytoxan 12 patients, taxol plus xeloda 9 patients. Results Seventy-six patients were evaluated for clinical response. There were CR 4 (5 .26 % ) , PR 49 (64 .47 % ), SD14 (18 .42 % ), PD9(11.84% ) .The total response rate was 69.74 %. Median time to progression (mTTP) was 8.3 months and median overall survival time was 9 .8 months. The main side effects were: decrease of leucocyte in 69 patients (90.79% ), alopecia in 70 patients ( 92 . 11 %), myodynia and arthrodynia in 61 patients ( 80. 26 %). There was no serious hypersensitivity. Conclusion Taxol-based chemotherapy is an effective and well tolerated regimen in the treatment of breast cancer. It can be used as the first-line therapy for advanced breast cancer.